


Your Fast Track to IND:

Rapid, Robust, Reliable Cell Line Development using Aragen's CHOMax™ Platform with Fut[∞]KO





Accelerate Speed to Clinic with Productivity, Precision & Confidence

Introducing Aragen's CHOMax™ platform with Fut[∞]KO—engineered for speed, precision, and maximum productivity. It features a glycoengineered GS KO cell line that supports full afucosylation, resulting in enhanced ADCC and improved therapeutic potency.

The Aragen Advantage

- Speed:** Rapid generation of RCB in 16 weeks
- Track Record:** 200+ programs completed successfully
- Royalty-Free:** CHO-GS and CHO-DG44 platforms
- Regulatory Acceptance:** Strong global presence of the platform with more than 110 licenses signed worldwide and over 86 accepted regulatory filings
- TnT Transposon Technology:** Enables efficient and highly stable gene integration
- High Productivity:** Minimum titers of 4 g/L for most mAbs and BsAbs, with titers up to 25 g/L post-intensification
- Scalability:** Excellent scalability across various bioreactor formats
- Comprehensive Support and Documentation:** Full traceability and detailed cell line history pack Regulatory Acceptance

Cell line Development Expertise



A Robust and Flexible CHO Expression Platform

RCB generation in CHOMax™ Platform with Fut[∞]KO in ~11-12 weeks



Our platform is consistently reviewed by global regulatory authorities, delivering industry-leading titers, streamlined processes, and comprehensive IND/BLA-ready documentation. From grams to kilograms in scale, Aragen reliably supports therapeutic CLD, diagnostic reagents, high-throughput screening, and critical bioanalytical requirements.

Partner with Aragen

Unlock the full potential of your biologics pipeline with a trusted partner committed to speed, precision, and quality.

Let's begin the conversation



For more information, contact bd@aragen.com
www.aragen.com

Stay Connected

